This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jiang, J. Articles by Cheng, L. Search for Related Content PubMed PubMed Citation Articles by Jiang, J. Articles by Cheng, L.

(American Journal of Pathology. 2002;160:667-671.)
© 2002 American Society for Investigative Pathology

Regular Articles

Expression of Group IIA Secretory Phospholipase A2 Is Elevated in Prostatic Intraepithelial Neoplasia and Adenocarcinoma

Jiazhong Jiang^*, Blake Lee Neubauer, Jeremy R. Graff, Marcio Chedid, James E. Thomas, Neal W. Roehm, Shaobo Zhang^*, George J. Eckert, Michael O. Koch, John N. Eble^* and Liang Cheng^*

From the Departments of Pathology^*
andUrology,
and the Division ofBiostatistics,
Indiana University School ofMedicine, Indianapolis; and the Lilly ResearchLaboratories,
Eli Lilly and Company, LillyCorporate Center, Indianapolis, Indiana

Phospholipase A2 (PLA2) enzymes release arachidonic acid from cellular phospholipids in a variety of mammalian tissues, including prostate. Group IIa secretory PLA2 (sPLA2) can generate arachidonate from cellular phospholipids. We examined the group IIa sPLA2 expression in benign prostatic tissues, prostatic intraepithelial neoplasia (PIN), and adenocarcinoma to determine whether sPLA2 expression is altered in the carcinogenesis of human prostatic cancer. Thirty-three of 74 total cases (45%) of benign prostatic tissue showed positive immunohistochemical staining for group IIA sPLA2, whereas 63 of 69 total cases (91%) of high-grade PINs and 70 of 78 total cases (90%) of adenocarcinomas gave positive results. Four of 10 cases of low-grade PIN showed positive immunoreactivity for sPLA2. The number of cells staining for sPLA2 was significantly less in benign epithelium (4%) and low-grade PIN (4%) compared to high-grade PIN (40%) or adenocarcinoma (38%) (P < 0.001). There was no significant difference between high-grade PIN and adenocarcinoma in the number of cells staining positively for sPLA2. The intensity of sPLA2 immunoreactivity was also different among benign prostatic tissue, low-grade PIN, high-grade PIN, and prostatic adenocarcinoma specimens. The malignant cells demonstrated more intense immunohistochemical staining (moderate to strong staining in 81% and 69% cases for high-grade PIN and adenocarcinoma, respectively) than benign glands (moderate staining in 11% of cases). No strong staining was observed in benign glands or low-grade PIN. Our data are consistent with the contention that group IIA sPLA2 expression is elevated in neoplastic prostatic tissue and support the hypothesis that dysregulation of sPLA2 may play a role in prostatic carcinogenesis.

This article has been cited by other articles:

				K. Ganesan, T. Ivanova, Y. Wu, V. Rajasegaran, J. Wu, M. H. Lee, K. Yu, S. Y. Rha, H. C. Chung, B. Ylstra, et al. Inhibition of Gastric Cancer Invasion and Metastasis by PLA2G2A, a Novel {beta}-Catenin/TCF Target Gene Cancer Res., June 1, 2008; 68(11): 4277 - 4286. [Abstract] [Full Text] [PDF]

				L. Linderoth, T. L. Andresen, K. Jorgensen, R. Madsen, and G. H. Peters Molecular Basis of Phospholipase A2 Activity toward Phospholipids with sn-1 Substitutions Biophys. J., January 1, 2008; 94(1): 14 - 26. [Abstract] [Full Text] [PDF]

				T L Cibull, T D Jones, L Li, J N Eble, L Ann Baldridge, S R Malott, Y Luo, and L Cheng Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J. Clin. Pathol., March 1, 2006; 59(3): 285 - 288. [Abstract] [Full Text] [PDF]

				T. M. Katona, B. L. Neubauer, P. W. Iversen, S. Zhang, L. A. Baldridge, and L. Cheng Elevated Expression of Angiogenin in Prostate Cancer and Its Precursors Clin. Cancer Res., December 1, 2005; 11(23): 8358 - 8363. [Abstract] [Full Text] [PDF]

				A. A Soler-Garcia, R. Maitra, V. Kumar, T. Ise, S. Nagata, R. Beers, T. K Bera, and I. Pastan The PATE gene is expressed in the accessory tissues of the human male genital tract and encodes a secreted sperm-associated protein Reproduction, April 1, 2005; 129(4): 515 - 524. [Abstract] [Full Text] [PDF]

				S. S. Jensen, T. L. Andresen, J. Davidsen, P. Hoyrup, S. D. Shnyder, M. C. Bibby, J. H. Gill, and K. Jorgensen Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids Mol. Cancer Ther., November 1, 2004; 3(11): 1451 - 1458. [Abstract] [Full Text] [PDF]

				P. Sved, K. F. Scott, D. McLeod, N. J. C. King, J. Singh, T. Tsatralis, B. Nikolov, J. Boulas, L. Nallan, M. H. Gelb, et al. Oncogenic Action of Secreted Phospholipase A2 in Prostate Cancer Cancer Res., October 1, 2004; 64(19): 6934 - 6940. [Abstract] [Full Text] [PDF]

				L. Cheng, C.-X. Pan, J.-T. Zhang, S. Zhang, M. S. Kinch, L. Li, L. A. Baldridge, C. Wade, Z. Hu, M. O. Koch, et al. Loss of 14-3-3{sigma} in Prostate Cancer and Its Precursors Clin. Cancer Res., May 1, 2004; 10(9): 3064 - 3068. [Abstract] [Full Text] [PDF]

				J. Sugimura, R. S. Foster, O. W. Cummings, E. J. Kort, M. Takahashi, T. T. Lavery, K. A. Furge, L. H. Einhorn, and B. T. Teh Gene Expression Profiling of Early- and Late-Relapse Nonseminomatous Germ Cell Tumor and Primitive Neuroectodermal Tumor of the Testis Clin. Cancer Res., April 1, 2004; 10(7): 2368 - 2378. [Abstract] [Full Text] [PDF]

				C.-X. Pan, M. S. Kinch, P. A. Kiener, S. Langermann, G. Serrero, L. Sun, J. Corvera, C. J. Sweeney, L. Li, S. Zhang, et al. PC Cell-Derived Growth Factor Expression in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma Clin. Cancer Res., February 15, 2004; 10(4): 1333 - 1337. [Abstract] [Full Text] [PDF]

				G. Zeng, Z. Hu, M. S. Kinch, C.-X. Pan, D. A. Flockhart, C. Kao, T. A. Gardner, S. Zhang, L. Li, L. A. Baldridge, et al. High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia Am. J. Pathol., December 1, 2003; 163(6): 2271 - 2276. [Abstract] [Full Text]

				H. W.M Niessen, P. A.J Krijnen, C. A Visser, C. J.L.M Meijer, and C Erik Hack Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res, October 15, 2003; 60(1): 68 - 77. [Abstract] [Full Text] [PDF]

				E. Boilard, S. G. Bourgoin, C. Bernatchez, and M. E. Surette Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2 Blood, October 15, 2003; 102(8): 2901 - 2909. [Abstract] [Full Text] [PDF]

				E. BOILARD, S. G. BOURGOIN, C. BERNATCHEZ, P. E. POUBELLE, and M. E. SURETTE Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans FASEB J, June 1, 2003; 17(9): 1068 - 1080. [Abstract] [Full Text] [PDF]

				S. Y. Leung, X. Chen, K. M. Chu, S. T. Yuen, J. Mathy, J. Ji, A. S. Y. Chan, R. Li, S. Law, O. G. Troyanskaya, et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis PNAS, December 10, 2002; 99(25): 16203 - 16208. [Abstract] [Full Text] [PDF]